DGIdb - OMEPRAZOLE Drug Record

OMEPRAZOLE chembl:CHEMBL1503 Approved

Alternate Names:

ANTRA
LOSEC MUPS
MOPRAL
OMERAN
PRILOSEC
MEZZOPRAM
H-168/68
H 168/68
ZANPROL
LOSEC
OMEPRAZOLE
OMEP
OMEPRAZOL
PRILOSEC®
OMEPRAZOLUM
LOSEC®
drugbank:00338
chembl:CHEMBL1503
pubchem.compound:4594
chemidplus:73590-58-6
rxcui:7646

Drug Info:

Year of Approval	1989
Drug Class	gi anti-ulcer agents, proton-pump inhibitors
FDA Approval	approved
Drug Class	small molecule
Drug Indications	antiulcer agent
Drug Indications	Proton pump inhibitor

(6 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Koyano S et al., 2005, Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population., Drug Metab Dispos
Dzeletovic N et al., 1997, Regulation of dioxin receptor function by omeprazole., J Biol Chem
Ozdemir et al., 2006, In vitro effects of some drugs on human red blood cell glucose-6-phosphate dehydrogenase enzyme activity., J Enzyme Inhib Med Chem
Fujisaki et al., 1998, Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats., Jpn. J. Pharmacol.
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Shi et al., 2008, Proton pump inhibitors: an update of their clinical use and pharmacokinetics., Eur. J. Clin. Pharmacol.
Tajima et al., 2008, Proton pump inhibitors and recurrent bleeding in peptic ulcer disease., J. Gastroenterol. Hepatol.
Kirchheiner et al., 2009, Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH., Eur. J. Clin. Pharmacol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Zuger B, 1978, Effeminate behavior present in boys from childhood: ten additional years of follow-up., Compr Psychiatry
Shin JM et al., 2009, The gastric HK-ATPase: structure, function, and inhibition., Pflugers Arch
Munson K et al., 2007, Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites., Biochemistry
Sachs G et al., 2006, Review article: the clinical pharmacology of proton pump inhibitors., Aliment Pharmacol Ther
Kashfi et al., 1995, Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human., Clin. Pharmacol. Ther.
Katagiri et al., 2005, Omeprazole raises somatostatin and motilin in human plasma., Biol. Pharm. Bull.
Yoshinari K et al., 2008, Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements., Biochem Pharmacol
Kountouras et al., Omeprazole and regulation of cytokine profile in Helicobacter pylori-infected patients with duodenal ulcer disease., Hepatogastroenterology
Swarovsky et al., 1994, Expression of the gastric H+/K(+)-ATPase and histidine decarboxylase during omeprazole treatment., Digestion
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Backlund et al., 1997, Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells., J. Biol. Chem.
Zhao W et al., 2018, Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug., Br J Clin Pharmacol
Gawrońska-Szklarz B et al., 2005, Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection., Eur J Clin Pharmacol
Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.
Mózsik et al., 2005, Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds., Inflammopharmacology
Handa et al., 2006, Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors., Inflamm. Res.
Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther
Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol

OMEPRAZOLE HDC

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8187977

Sources:
NCI
OMEPRAZOLE ATP4A

Interaction Score: 1.61

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CGT-2168

Novel drug target Established target

Mechanism of Interaction Potassium-transporting ATPase inhibitor

PMIDs:
18679668 19120905 18925391 11752352 679668 18536934 17425287 16700898

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
OMEPRAZOLE VIP

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15684503

Sources:
NCI
OMEPRAZOLE HEXB

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9593221

Sources:
NCI
OMEPRAZOLE TAC1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16259735 15684503

Sources:
NCI
OMEPRAZOLE IL1B

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21054464 16815316 14638340

Sources:
PharmGKB
OMEPRAZOLE ATP4B

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Potassium-transporting ATPase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
OMEPRAZOLE AHR

Interaction Score: 0.1

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
15860653 9139728

Sources:
PharmGKB
OMEPRAZOLE CSF2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11100337

Sources:
NCI
OMEPRAZOLE GSTP1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8529327

Sources:
NCI
OMEPRAZOLE CXCL8

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17122965

Sources:
NCI
OMEPRAZOLE HSPB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE TNF

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16815316

Sources:
NCI
OMEPRAZOLE G6PD

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16570509

Sources:
NCI
OMEPRAZOLE MCL1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
OMEPRAZOLE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29377228 15976989

Sources:
PharmGKB
OMEPRAZOLE NR1I2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OMEPRAZOLE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 18502397

Sources:
DTC PharmGKB
OMEPRAZOLE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528 9395520 22931300

Sources:
DTC NCI PharmGKB
OMEPRAZOLE PLK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE CBX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
OMEPRAZOLE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC FDA
OMEPRAZOLE HPGD

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE KDM4E

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
OMEPRAZOLE BAZ2B

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE MAPT

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE KDM4A

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE VDR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: OMEPRAZOLE
- Version: 01-August-2011
Alternate Names:

OMEPRAZOLE Primary Drug Name

Drug Info:

Drug Class gi anti-ulcer agents, proton-pump inhibitors

Year of Approval 1989

Publications:
TdgClinicalTrial: OMEPRAZOL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiulcer agent

Drug Class small molecule

FDA Approval approved

Publications:
TdgClinicalTrial: OMEPRAZOLE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiulcer agent

Drug Class Small Molecule

FDA Approval approved

Publications:
DTC: OMEPRAZOLE
- Version: 02-September-2020
Alternate Names:

CHEMBL1503 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

NCI: OMEPRAZOLE

Version: 14-September-2017

Alternate Names:

C716 NCI drug code

Drug Info:

Publications:

Katagiri et al., 2005, Omeprazole raises somatostatin and motilin in human plasma., Biol. Pharm. Bull.

Mózsik et al., 2005, Participation of vanilloid/capsaicin receptors, calcitonin-gene-related peptide and substance P in gastric protection of omeprazole and omeprazole-like compounds., Inflammopharmacology

Handa et al., 2006, Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors., Inflamm. Res.

PharmGKB: omeprazole

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.

Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther

Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol

TTD: Omeprazole
- Version: 2020.06.01
Alternate Names:

D01XNB TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1503
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Omeprazole
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1503
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	CGT-2168
Novel drug target	Established target
Mechanism of Interaction	Potassium-transporting ATPase inhibitor

Mechanism of Interaction	Potassium-transporting ATPase inhibitor
Direct Interaction	yes

OMEPRAZOLE Drug Record

OMEPRAZOLE chembl:CHEMBL1503 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8187977

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CGT-2168 Novel drug target Established target Mechanism of Interaction Potassium-transporting ATPase inhibitor

PMIDs: 18679668 19120905 18925391 11752352 679668 18536934 17425287 16700898

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15684503

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9593221

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16259735 15684503

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21054464 16815316 14638340

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Potassium-transporting ATPase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 15860653 9139728

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11100337

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8529327

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17122965

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16815316

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16570509

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29377228 15976989

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300 18502397

Interaction Types & Directionality:

n/a

PMIDs:
8187977

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CGT-2168

Novel drug target Established target

Mechanism of Interaction Potassium-transporting ATPase inhibitor

PMIDs:
18679668 19120905 18925391 11752352 679668 18536934 17425287 16700898

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
15684503

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9593221

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16259735 15684503

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21054464 16815316 14638340

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Potassium-transporting ATPase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

agonist (activating)

PMIDs:
15860653 9139728

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11100337

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8529327

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17122965

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16815316

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16570509

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29377228 15976989

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300 18502397

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9187528 9395520 22931300

Sources:
DTC NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC